NKTX Key Statistics, Chart & Performance
The current stock price of NKTX is 2.0015 USD. In the past month the price increased by 7.69%. In the past year, price decreased by -20.65%.
NKTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NKTX. When comparing the yearly performance of all stocks, NKTX is a bad performer in the overall market: 84.75% of all stocks are doing better.
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. NKTX has a great financial health rating, but its profitability evaluates not so good.
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 26.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.02% | ||
| ROE | -30.37% | ||
| Debt/Equity | 0 |
NKTX Forecast & Estimates
13 analysts have analysed NKTX and the average price target is 12.04 USD. This implies a price increase of 501.35% is expected in the next year compared to the current price of 2.0015.
NKTX Ownership
NKTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.79 | 380.57B | ||
| AMGN | AMGEN INC | 15.06 | 177.30B | ||
| GILD | GILEAD SCIENCES INC | 15.11 | 153.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.52 | 112.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 705.94 | 47.56B | ||
| INSM | INSMED INC | N/A | 34.40B | ||
| NTRA | NATERA INC | N/A | 32.30B | ||
| BIIB | BIOGEN INC | 9.84 | 24.17B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.59B | ||
| INCY | INCYTE CORP | 16.44 | 20.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 19.88B |
Related stock screener links
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Company Info
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 105
Phone: 19254071049
NKARTA INC / NKTX FAQ
What does NKARTA INC do?
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
What is the stock price of NKARTA INC today?
The current stock price of NKTX is 2.0015 USD. The price increased by 2.12% in the last trading session.
Does NKTX stock pay dividends?
NKTX does not pay a dividend.
How is the ChartMill rating for NKARTA INC?
NKTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is NKARTA INC worth?
NKARTA INC (NKTX) has a market capitalization of 142.17M USD. This makes NKTX a Micro Cap stock.
Can you provide the upcoming earnings date for NKARTA INC?
NKARTA INC (NKTX) will report earnings on 2026-05-12.
What is the outstanding short interest for NKARTA INC?
The outstanding short interest for NKARTA INC (NKTX) is 16.13% of its float.